Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
我們正在追蹤 Insilico Medicine 的市場擴張
過去 90 日內有 16 個訊號。
Insilico Medicine 的國際擴張與競爭對手的比較
Insilico Medicine你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Insilico Medicine你 | 0 | 0 | — | 0 | 0 |
Machine Learning Engineer
查看招聘Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates · 上個月
Business Development Manager - AI Platform Technologies
查看招聘Tokyo, Japan · 2個月前
Clinical Project Manager (Oncology) Consultant
查看招聘United States · 2個月前
Most frontier models continue to miss the mark on critical ADMET and toxicity tasks. Domain expertise isn't solved by prompt tuning alone, it requires specialized training.Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.We’re ready to help you integrate these models dire ...
進行中
Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.
進行中
Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.
進行中Insilico Medicine成立業界首個長壽委員會,由禮來公司Andrew Adams領導,監督AI驅動的衰老研究和藥物發現,針對生物衰老過程和健康壽命延長。
英矽智能成立行業首個長壽委員會,為AI驅動的衰老研究和藥物發現提供科學監督,專注於同時針對衰老和疾病機制的雙重用途靶點開發。
英矽智能提名ISM0387為第30款AI驅動臨床前候選藥物,也是首個在阿聯酋研發的候選藥物,針對膠質母細胞瘤的MTA協同PRMT5抑制劑,利用生成式AI平台12個月內完成。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Insilico Medicine 業務、市場及增長訊號的快速解答。
